Follow-up statement relating to SARS-CoV-2 – CoVig-19 Plasma Alliance news and update on supply of plasma-derived therapies and recombinant products for persons with hemophilia and von Willebrand disease (VWD)

Further to our previous correspondence, we would like to provide an update on the CoVig-19 Plasma Alliance, as well as supply of Takeda’s plasma-derived therapies and recombinant products for persons with hemophilia and VWD, as the SARS-CoV-2 outbreak continues.

Last week we announced some important progress regarding the continued expansion and activities of the CoVig-19 Plasma Alliance, the plasma industry collaboration recently established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19. We are working hard with our Alliance members and other large organizations outside of the plasma industry to amplify awareness and encourage convalescent plasma donations from anyone who has recovered from COVID-19. The full announcement and details of these efforts can be accessed here, along with further information on the CoVig-19 Plasma Alliance website. The success of the CoVig-19 program depends heavily right now on the support of people across the world to donate convalescent plasma. We therefore encourage you to help us raise awareness among your member organizations and the people they represent. If there is a way that we can support you appropriately to make that happen, please do not hesitate to let us know.

In terms of the supply of our treatment, since our last update we continue to monitor how the pandemic situation is evolving and how it impacts our global supply chain. We would like to reassure you that we continue to foresee no near-term disruption in the planned supply of our products, including plasma-derived therapies and recombinant products for persons with hemophilia and VWD. We manufacture certain products in our own facilities within our global manufacturing network, in addition to sourcing certain other products from over 130 qualified third-party contract manufacturers within our global network. Specifically for our plasma-derived therapies, all of our plasma collection centers remain open and we are pleased to share that our planned expansion is still on track, with 23 new centers opening across the US and Europe throughout the rest of the year. We will continue to provide you with updates as needed.

As always, our top priority is to do all we can to make sure our medicines and services continue to reach the individuals who rely on them, while we protect the health of our employees, those who work alongside them, their families and our communities.

Should you have additional questions, please contact:

Tineke Zuurbier, Global Patient Advocacy, Rare Hematology tineke.zuurbier@takeda.com

Yours sincerely,

Alvaro Herreros Arregui
Global Head of Franchise, Rare Hematology Takeda